A Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma [IMmotion150]

Clinical Trial ID NCT01984242

PubWeight™ 14.57^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01984242

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.	Cancer Prev Res (Phila)	2015	2.17
2	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2015	1.06
3	Clinical impact of checkpoint inhibitors as novel cancer therapies.	Drugs	2014	0.99
4	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.	Ther Adv Urol	2015	0.88
5	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.	Cancer J	2014	0.88
6	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.	Onco Targets Ther	2014	0.85
7	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.	Cancer Immunol Res	2014	0.85
8	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.	Nat Rev Urol	2016	0.84
9	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.	Semin Oncol	2015	0.82
10	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential.	Ther Adv Med Oncol	2015	0.82
11	Immunobiology and immunotherapy in genitourinary malignancies.	Ann Transl Med	2016	0.78
12	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.	Urol Oncol	2015	0.78
13	Challenges and future perspectives of T cell immunotherapy in cancer.	Immunol Lett	2015	0.78
14	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.	Oncoimmunology	2015	0.77
15	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.	BioDrugs	2014	0.76
16	Medical treatment of renal cancer: new horizons.	Br J Cancer	2016	0.76